Telix Pharmaceuticals (ASX: TLX) has completed the acquisition of RLS (USA) Inc., America’s only Joint Commission- accredited radiopharmacy network distributing PET1, SPECT2 and therapeutic radiopharmaceuticals.
The acquisition immediately enhances Telix’s presence in the US, with a network of over 30 radiopharmacies dispensing radiopharmaceuticals manufactured by Telix and other companies, while bringing a team of highly-skilled and multi-disciplinary radiopharmaceutical professionals into the company.
The acquisition is part of Telix’s strategy to establish an integrated radiopharmaceutical ecosystem, enhancing its ability to deliver novel therapeutic and diagnostic radiopharmaceuticals to patients.
The RLS footprint of over 100,000 square feet of appropriately licensed expansion space provides the opportunity to build a next-generation radiometal production network to benefit Telix, select commercial partners, and patients.
RLS will continue to operate under the same name and as a standalone business within Telix Manufacturing Solutions (TMS), which includes other key Telix brands with multi-vendor and third- party relationships such as ARTMS, IsoTherapeutics and Optimal Tracers.
The addition of RLS’s operations will significantly strengthen Telix’s commercial infrastructure and distribution capabilities in its largest market, including the capacity to undertake in-house cyclotron manufacturing powered by Telix’s ARTMS QUANT Irradiation System (QISTM) cyclotron technology, enabling standardized, high-efficiency and cost-effective production of radiometals.
“We are pleased to officially welcome the RLS team to Telix. The completion of this acquisition marks a milestone in our journey to become the leader in radiopharmaceuticals, as the RLS network significantly boosts our existing in-house and partner capabilities,” Dr. Christian Behrenbruch, Telix Managing Director and Group Chief Executive Officer, said.
“With RLS’s distribution and operational expertise, Telix is strongly positioned to bring our growing portfolio of innovative products to more patients across the US.”